11 results about "Cardiac dysfunction" patented technology

The application relates to the fields of medical diagnosis and gene drugs, and particularly relates to application of long-chain non-coding RNA in preparation of a heart insufficiency diagnosis reagent or kit. The application also provides application of the long-chain non-coding RNA in preparation of a heart insufficiency treatment drug. The application first finds that LOC107984012 is long-chain non-coding RNA which is highly expressed in a failing heart, and provides a new diagnosis marker and treatment target for heart insufficiency.

This invention discloses the application of GW3965 in the preparation of drugs that alleviate cardiac damage caused by doxorubicin. Experiments have demonstrated that GW3965 can, while inhibiting tumor growth, alleviate cardiac dysfunction related to doxorubicin cardiotoxicity, reduce doxorubicin-induced cardiac fibrosis, and inhibit doxorubicin-induced cardiomyocyte atrophy and apoptosis. This suggests that GW3965 can alleviate cardiac damage caused by doxorubicin, increase the safety of doxorubicin chemotherapy, and has promising clinical application prospects.

The present invention is related to a composition comprising a novel chemical compound with the chemical Name "4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol" and its use. The 4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol and related compounds are useful for treating microgravity induced damage such as skeletal muscle atrophy and dysfunction as well as cardiac dysfunction and are also useful for human diseases and conditions accompanied by significant loss of muscle mass and reduced endurance capacity, such as immobilized patients, cancer, heart failure, sepsis, diabetes mellitus, muscle genetic diseases and neurodegenerative disorders. In addition, 4-(4-((4- Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2-isopropylphenol and related compounds are useful for treating human diseases related to muscle degeneration and ageing such as sarcopenia and heart failure.

The present invention relates to 4-oxoretinoate for use in treatment or prevention of cardiac dysfunction, heart failure, or adverse cardiac remodelling after myocardial infarction or impaired cardiac blood flow. The present invention also relates to 4-oxoretinoate for use in treatment of coronary artery disease, or of ischemia-reperfusion injury.

Introduced here approaches to developing, training, and implementing algorithms to cardiac dysfunction through automated analysis of physiological data. As an example, a model may be developed and then trained to quantify left and right ventricular dysfunction using electrocardiogram waveform data that is associated with a population of individuals who are diverse in terms of age, gender, ethnicity, socioeconomic status, and the like. This approach to training allows the model to predict the presence of left and right ventricular dysfunction in a diverse population. Also introduced here is a regression framework for predicting numeric values of left ventricular ejection fraction.

The application discloses an early evaluation system for diastolic heart dysfunction, and relates to the technical field of medical treatment. IVR and SR E ; a storage module is used for storing the normal reference ranges of SR IVR and SR E of healthy people in different age groups; an evaluation output module is used for comparing the SR IVR and SRE of the examinee with the normal reference ranges in the storage module, and outputting the early evaluation result of the diastolic heart dysfunction; the secondary screening is conducted on the hypertensive patients who cannot be diagnosed as having the diastolic heart dysfunction through the conventional ultrasound, so that the basis for early intervention is provided, and the incidence of the diastolic heart failure can be reduced.

1. The name of the design product: IABP host trolley. 2. The use of the design product: for clinical first aid of severe coronary heart disease such as cardiac insufficiency, myocardial infarction, cardiogenic shock, etc. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 2. 5. The bottom view of the design product is not easy to see or not visible during use, and the bottom view is omitted.

The present invention pertains to a peptide of the S100A1 protein for use in the treatment or prevention of antineoplastic agent-mediated cytotoxicity or cancer therapy-related cardiac dysfunction (CTRCD) or cancer therapy-related heart failure (CTRHF), as well as nucleic acids encoding said peptide, vectors comprising said nucleic acid, host cells comprising the vector or nucleic acid and expressing it, and to respective pharmaceutical compositions.

The present invention relates to a composition comprising bindarit for preventing, alleviating or treating heart disease. The composition promotes survival and proliferation of endothelial cells and regulates cell stress and apoptosis, and thus has an effect of preventing, alleviating or treating heart disease and alleviating cardiac dysfunction caused by the disease.

The application discloses application of 1,2,3,4,6-O-galloyl glucose in preparation of a drug for preventing and / or treating myocardial hypertrophy, and belongs to the technical field of biological medicine. The application proves for the first time that PGG can significantly improve cardiac dysfunction induced by TAC operation, inhibit increase of heart volume and weight, myocardial cell hypertrophy, down-regulate expression of myocardial hypertrophy markers Nppa, Nppb and Myh7, and block excessive activation of an AKT / ERK signal path. Therefore, PGG can effectively prevent and / or treat pathological myocardial hypertrophy, and has a clear clinical application prospect.